Sanofi (NASDAQ:SNY) Holdings Lowered by Primecap Management Co. CA

Primecap Management Co. CA trimmed its stake in shares of Sanofi (NASDAQ:SNY) by 0.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,110,928 shares of the company’s stock after selling 5,070 shares during the period. Primecap Management Co. CA’s holdings in Sanofi were worth $53,580,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of SNY. Raymond James Financial Inc. purchased a new stake in Sanofi in the 4th quarter worth about $135,933,000. Jennison Associates LLC lifted its stake in Sanofi by 938.0% in the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after acquiring an additional 1,720,972 shares in the last quarter. DAVENPORT & Co LLC lifted its stake in Sanofi by 40.7% in the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock worth $110,715,000 after acquiring an additional 664,455 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after acquiring an additional 399,301 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in Sanofi by 13.1% in the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after acquiring an additional 395,744 shares in the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on SNY shares. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $60.00.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $59.11 on Wednesday. The business has a 50 day moving average price of $54.03 and a 200 day moving average price of $52.85. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12. The company has a market cap of $150.01 billion, a price-to-earnings ratio of 23.74, a PEG ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Research analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.